Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis — Kristian Reich (2021) | RDL Network
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis
Article 2021 en
Authors
KR
Kristian Reich
UM
Ulrich Mrowietz
AM
Alan Menter
Abstract
1 min read
Greater achievement of PASI ≤2 was observed in patients with more moderate vs. more severe skin disease. Apremilast may be particularly beneficial in more moderate disease early in the treatment paradigm.
Matthias Augustin, C. Elise Kleyn, Curdin Conrad, Paul Sator, Mona Ståhle, Kilian Eyerich, M.A. Radtke, Christine Bundy, L. Mellars, Chiara Greggio, Myriam Cordey, V. Koscielny, Christopher Em Griffiths
Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher Em Griffiths
Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp
Ulrich Mrowietz, Knud Kragballe, Kristian Reich, Phyllis I. Spuls, Christopher Em Griffiths, Alexander Nast, J Franke, C. Antoniou, Petr Arenberger, Flora Balieva, Matilda Bylaitė, Osvaldo Correia, E. Daudén, Paolo Gisondi, Lars Iversen, Lajos Kemény, M. Lahfa, Tamar Nijsten, Tapio Rantanen, Adam Reich, T. Rosenbach, Siegfried Segaert, Catherine Smith, T. Talme,
Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Tiago Torres, Zoran Popmihajlov, Ying-Ming Jou, Misti Linaberry, Carolin Daamen, Christopher Em Griffiths
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.